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HISTORICAL OVERVIEW
In 1886, Dr Pierre Marie used the term ‘‘acromegaly’’ for
the first time and described the full clinical characteristics of
this condition (1). However, twenty-two years prior in 1864,
Dr. Andrea Verga had already named the same disorder
‘‘prosopo-ectasia’’ [widening of the face] (2). At the
postmortem examination of an acromegalic woman (with
‘‘prosopo-ectasia’’), he found a walnut-sized sellar tumor
and displacement of the optic nerves (2). A normal pituitary
gland was not found. He wondered whether the normal
pituitary gland had disappeared because of pressure from
the tumor or whether the tumor itself was a degeneration of
the gland (2). Also, Dr. V. Brigidi described in 1877 a case
report that included findings obtained at the autopsy of the
acromegalic Italian actor Ghirlenzoni (3). Dr. V. Brigidi had
diagnosed this condition as ‘‘rheumatitis deformans’’ and
made the significant observation of a hypertrophied
pituitary gland on the first microscopic examination of a
pituitary tumor (3). In 1887, Dr. Oskar Minkowski reported
that pituitary enlargement is found in all postmortem
studies on patients with acromegaly (4). In 1892, Dr.
Roberto Massalongo was able to correlate acromegaly with
increased pituitary function by demonstrating that a
pituitary tumor taken from a patient with acromegaly
contained specific granulated cells (5). At the end of the 19th
century, the relationship between pituitary hyperfunction-
hypertrophy (or a hyperfunctioning pituitary tumor) and
acromegaly was clearly established and confirmed by many
investigators (6–12). Dr. Henri Henrot had already pub-
lished in 1877 an autopsy report of a patient with gigantism,
in whom a 4.563.0 cm tumor was found in the position of
the pituitary body (13,14).
Initially, it was believed that acromegaly and gigantism
were two totally different diseases. Dr. Pierre Marie (15–21),
his intern Dr. J.D. Souza-Leite (22) and Dr. Georges Guinon
(23) were convinced that acromegaly and gigantism were
two entirely different disorders. Gigantism was considered
an exaggerated variant of normal development, whereas
acromegaly was considered as a pathological condition.
However, in 1884, Drs. Christian F. Fritsche and Theodor
Albrecht Edwin Klebs (24), supported by the work of Dr.
Karl Langer (1872) (25), concluded that in contrast to
gigantism, which they considered a congenital disorder,
acromegaly is an acquired variety of gigantism that occurs
at a later age after growth is completed. In 1894, Dr. M.
Sternberg concluded that there are many similarities
between acromegaly and gigantism (26). However, in 1897
he changed his view and agreed with Dr. Pierre Marie and
others that both disorders have different origins (27). In
1891, Dr. D.J. Cunningham, after studying the skeleton of
the Irish giant Cornelius Magrath (1736–1760; height: 2.26 m
[7 ft, 5 in]), pointed out the connection between acromegaly
and gigantism (28–30). In 1893, Dr. Charles Dana (31) and
Dr. Woods Hutchinson (32) described the case report and
postmortem studies of the French giantess Emma Aline
Bataillard (also known as Lady Aama, 1877–1895; height:
2.03 m [6 ft, 8 in]) and reached the same conclusion. After
studying the acromegalic giant Jean-Pierre Mazas (1847–
1901; height: 2.30 m [7 ft, 6K in]), the so-called ‘‘giant of
Montastruc’’ (Monastruc, Haute-Garonne, France) in 1895,
Drs. E´douard Brissaud and Henry Meige also concluded
that acromegaly and gigantism can coexist in the same
person (33,34).
It gradually became evident that acromegaly and gigant-
ism have the same pathogenetic mechanism, but differ
regarding the age of onset. Gigantism occurs much earlier in
life when the skeleton still has the potential to grow, a
developmental phase now known as ‘‘prepubertal’’ (33–35).
Finally, the cause of acromegaly and gigantism — the
overproduction of pituitary growth hormone — became
known in the early years of the 20th century (36).
Familial acromegaly and familial gigantism are extremely
rare. The earliest report of familial gigantism may be that
of Goliath, described in in the Bible, where it is stated that
his father and three brothers were also giants. The first
description of familial acromegaly in the medical literature
is most likely a report by Fraenkel that was published in
1901 (37,38). The Ugo brothers, or Hugo brothers, also
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known in France as ‘‘les Ge´ants des Alpes’’ (‘‘the Giants of
the Alps’’) (Figure 1), were two famous giants who traveled
the world and appeared at fairs and circuses at the end of
the 19th century and the beginning of the 20th century.
Battista Ugo (in French: Baptiste Hugo, 1876–1916) attained
a height of 2.30 m (7 ft, 7 in) and Paolo Antonio Ugo (in
French: Antoine Hugo, 1887–1914) attained a height of
2.25 m (7 ft, 5 in) (39–41). Their parents, three brothers and
two sisters were of average size. The postmortem examina-
tion of Baptiste Hugo was performed and published by Dr.
D. Symmers at the William Parker Hospital in New York.
The report describes a pituitary adenoma measuring
56 2.56 2.3 cm (26 16 0.9 in) and weighing 5.94 g with
suprasellar expansion that compressed both optic nerves.
Left parasellar and retrosellar expansion were also found.
In his famous monograph, ‘‘The Pituitary Body and its
Disorders’’, published in 1912, Dr. Harvey Cushing (42)
hinted at ‘‘Mendelian tendencies’’ in two patients with
familial gigantism (case XIII, surgical No. 27784, pp. 8–92;
case XXXI, surgical No. 27011K, pp. 158–162) (42).
Since these initial reports, several authors have reported
the coincidence of acromegaly and gigantism in first-degree
relatives (43–55).
Clinical relevance
Growth hormone (GH)-secreting pituitary adenomas have
an annual incidence of about 3 per 1,000,000 and a prevalence
of about 60 per 1,000,000. The likelihood of multiple GH-
secreting tumors presenting among first-degree relatives
within a single family is, therefore, statistically very un-
common, and their occurrence has prompted many research-
ers to consider this an inheritable disorder (56).
Familial GH-secreting tumors are seen in association with
three separate hereditary clinical syndromes: (1) multiple
endocrine neoplasia type 1 (MEN1), (2) Carney complex
(CNC), and (3) familial isolated pituitary adenomas (FIPA).
Multiple endocrine neoplasia type 1 (MEN1)
Autosomal-dominant MEN1 syndrome is associated with
a loss of heterozygosity (LOH) on chromosome locus 11q13
(57). The MEN1 gene tumor suppressor gene encodes a
610-amino acid protein known as menin. More than 550
mutations of the MEN1 gene have been identified. Pituitary
tumors occur in approximately 30–50% of patients with
MEN1 (58), but the frequency of GH-producing pituitary
tumors in MEN1 patients is only about 10% (59).
Carney complex (CNC)
Pituitary adenomas occur in 10–20% of patients with the
autosomal-dominant CNC, and these are invariably GH-
secreting tumors (60).
CNC is associated with a LOH on chromosomal locus
17q22–24. Germline mutations in the protein kinase A
(PKA) regulatory subunit 1 (PRKAR1A) gene have been
identified (61). Loss of function of this regulatory subunit
results in constitutive activation of PKA that increases
signaling through a pathway that enhances proliferation of
the GH-producing cells in the pituitary.
Familial isolated pituitary adenomas (FIPA)
Inactivating germline mutations in the aryl hydrocarbon
receptor that interacts with tumor suppressor protein (AIP)
can be found in 40–50% of families that have a case of
acromegaly occurring along with FIPA (62–66). To date,
about 50 different AIP mutations have been identified.
AIP mutation-positive acromegaly or gigantism is gen-
erally diagnosed 10 years earlier than sporadic acromegaly.
GH-producing tumors in AIP-positive patients (mostly
males) more frequently display extrasellar growth, exhibit
more aggressive characteristics, and have a tendency for
higher accelerated growth than sporadic tumors. These
tumors are also more frequently associated with onset
in childhood and adolescence, thus presenting more
frequently with gigantism (67,68). Furthermore, AIP muta-
tion-positive GH-producing tumors appear to be less
responsive to medical therapy with somatostatin analogs
and dopamine agonists.
In 2010, Chahal and co-workers extracted DNA from a
tooth of the Irish giant, Charles Byrne (1761–1783; 2.31 m,
[7 ft 7 in]), and identified a germline mutation in the AIP
gene. Four contemporary Northern Irish families who
Figure 1 - Familial gigantism in the two Hugo brothers. Top row:
Battista Ugo (Baptiste Hugo), 1876–1916, reached a height of
2.30 m (7 ft, 7 in) and Paolo Antonio Ugo (Antoine Hugo), 1887–
1914, reached a height of 2.25 m (7 ft, 5 in). Bottom row: the
parents of the Ugo brothers, Teresa Chiardola (1849–1905) and
Antonio Ugo (1840–1917), and their sister, Maddalena Ugo
(1885–1960). Picture from the collection of Dr. W. W. de Herder.
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presented with gigantism, acromegaly, or prolactinoma
have the same mutation and haplotype associated with the
mutated gene. Using coalescent theory, they came to the
conclusion that these persons share a common ancestor who
lived about 57–66 generations earlier (69).
Familial acromegaly and gigantism only account for a
very tiny proportion of all pituitary adenomas and can be
related to MEN 1 and CNC syndromes as well as to
mutations in the AIP gene. AIP mutations are very common
in gigantism.
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